Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Sanofi Global Health

    - PMLiVE

    Sanofi reports improved patient outcomes from high-dose influenza vaccine

    Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

    - PMLiVE

    Medscape Education Returns as Thought Leaders to AIS 2025

    📍 September 8–10, 2025 Hilton at Penn’s Landing | Philadelphia, PA Medscape Education is proud to return to the 2025 Alliance Industry Summit (AIS) as a Silver Sponsor and leading...

    Medscape Education

    - PMLiVE

    Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

    Sha joined Sanofi in 2019 and takes up her new role with immediate effect

    - PMLiVE

    What Do Pickleball and Medscape Education Have in Common? Heather Lavigne.

    When she’s not taking on challengers on the pickleball court, you can find Heather Lavigne leading Medscape Education’s dynamic insights and impact team as Senior Director. Her leadership philosophy is...

    Medscape Education

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

    Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    - PMLiVE

    Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

    The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links